ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1720

FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus

Ritu Bohat1, Chunyu Xu1, Xiaofang Liang1, Yanping Chen1, Ningbo Zheng1, Roshni Jaffery1, Ashley Guerrero1, Nicholas Egan1, John Hicks2, Chandra mohan1 and Weiyi Peng1, 1University of Houston, Houston, TX, 2Baylor College of Medicine, Houston, TX

Meeting: ACR Convergence 2022

Keywords: genetics, Mouse Models, Lupus, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Sle1 and FASlpr are two lupus susceptibility loci that lead to manifestations of systemic lupus erythematosus (SLE) by altering the FAS/FASL pathway and adaptive immunity. Although C57BL/6 (B6) mice bearing either of these genes display mild phenotypes, the epistatic interaction of Sle1 and FASlpr results in severe lupus, confirming that these two genes impact non-redundant, pathways. Here, we aim to evaluate whether FASlpr exhibits gene dosage effects in determining cellular and serological phenotypes associated with lupus.

Methods: B6, B6.FASlpr/lpr (lprhomo), B6.Sle1/Sle1 (sle1), B6.Sle1/Sle1.FASlpr/+ (sle1.lprhet), and B6.Sle1/Sle1.FASlpr/lpr (sle1.lprhomo) mice were bred and examined at three different ages: 2-3 month (mo), 4-8 mo, 10-12 mo. Serum levels of antinuclear antibody (ANA) and cytokines were determined by ELISA and Luminex, respectively. The cellular composition and function of immune cells in spleen and kidney tissues were characterized by flow cytometry. Urine protein level and pathology were used to evaluate renal damage.

Results: Sle1.lprhomo mice exhibited prominent splenomegaly and lymphadenopathy, associated with early mortality (median lifespan = 4 mo). In contrast, sle1.lprhet mice exhibited a lifespan comparable to sle1 mice (100% alive at 12 mo age), with no evidence of splenomegaly or lymphadenopathy till 12 mo of age. Compared to the sle1 and lpr controls, sle1.lprhet mice exhibited significantly elevated serum IgG anti-dsDNA antibodies, from 4 mo of age (p< 0.05), with the phenotype being more prominent in females. Similar to the serological differences, sle1.lprhet mice exhibited increased proteinuria compared to the single gene controls. Renal pathology assessment is in progress.

To elucidate the mechanistic basis for the observed differences, further cellular, and serological phenotyping was carried out. The percentages of immune subsets including CD4/CD8 T cells, B cells, monocytes, and NK cells in spleens from sle1.lprhet mice at 4-8 mo were comparable with those in the single gene controls. However, when cultured ex-vivo, sle1.lprhet T-cells had an increased propensity to differentiate into both Th1 and Th2 cells, compared to the single gene controls. In contrast, homozygous mutation of FASlpr led to reduced T-reg cells, with profound skewing to effector/memory T-cells, increased CD4:CD8 ratios, and Ki67+ proliferating cells, features associated with lymphoproliferative disease. Indeed homozygous absence of FAS was necessary to upregulate 24 out of 36 serum cytokines interrogated. In contrast, gene dose effects of FASlpr were noted in upregulating serum IL-1 alpha, IL-2 and IL-27.

Conclusion: In contrast to sle1.lprhomo mice which exhibit profound lymphoproliferation and early mortality, sle1.lprhet mice is a more faithful model of human SLE based on its serological and renal phenotypes, without the confounding effect of lymphoproliferation. Whereas the complete absence of FAS leads to impaired activation induced cell death, reduced levels of FAS may regulate T-cell differentiation and production of key cytokines implicated in autoimmunity, including IL-1 alpha, IL-2 and IL-27.


Disclosures: R. Bohat, None; C. Xu, None; X. Liang, None; Y. Chen, None; N. Zheng, None; R. Jaffery, None; A. Guerrero, None; N. Egan, None; J. Hicks, None; C. mohan, None; W. Peng, Fresh Wind Biotechnologie.

To cite this abstract in AMA style:

Bohat R, Xu C, Liang X, Chen Y, Zheng N, Jaffery R, Guerrero A, Egan N, Hicks J, mohan C, Peng W. FASlpr Gene Dosage Differentiates Lymphoproliferative from Non-lymphoproliferative Autoimmunity – a Novel Mouse Model of Lupus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/faslpr-gene-dosage-differentiates-lymphoproliferative-from-non-lymphoproliferative-autoimmunity-a-novel-mouse-model-of-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/faslpr-gene-dosage-differentiates-lymphoproliferative-from-non-lymphoproliferative-autoimmunity-a-novel-mouse-model-of-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology